Pediatric Nephrology

, Volume 18, Issue 11, pp 1138–1142 | Cite as

Cyclosporin A for the treatment of severe Henoch-Schönlein glomerulonephritis

  • Jaana Ronkainen
  • Helena Autio-Harmainen
  • Matti NuutinenEmail author
Original Article


We evaluated the efficacy of cyclosporin A (CyA) for treating pediatric patients with severe Henoch-Schönlein glomerulonephritis (HSP-GN) and nephrotic-range proteinuria. Seven pediatric HSP-GN patients (5 boys, 2 girls) were treated with CyA, with a mean age of 10.6 years at diagnosis (range 7.2–15.2 years) and mean follow-up times of 6.0 years (range 4.4–8.9 years) from diagnosis and 5.2 years (range 3.4–7.7 years) from the beginning of the CyA treatment. All had developed nephrotic-range proteinuria within 1–3 months of the HSP diagnosis. A renal biopsy was performed on all the patients, and two showed rapidly progressive glomerulonephritis. They all received additional angiotensin converting enzyme inhibitor medication and one to three types of immunosuppressive treatment had been tried in five of the seven patients before CyA was initiated at a mean interval of 0.7 years after diagnosis (range 0.1–2.0 years). All the patients responded to the CyA treatment within a mean of 1.4 months (range 1 week to 4 months). Four patients achieved a stable remission and had been without CyA treatment for a mean of 3.7 years (range 2.9–5.3 years) by the end of the follow-up. Three patients seemed to become CyA dependent, since they developed proteinuria when the treatment was stopped. CyA treatment had been started significantly earlier (P=0.045) in the former group (mean 0.2 years, range 0.1–0.3 years) than in the latter (mean 1.5 years, range 1.2–2.0 years). Renal function was preserved in all patients, the glomerular filtration rate, plasma cystatin C, serum albumin, and serum creatinine being within normal limits at the end of the follow-up. We conclude that CyA treatment for severe treatment-resistant HSP-GN is promising, since four of the seven patients enjoy stable remission and all have retained their renal function after a mean follow-up of 6.0 years. However, some patients seem to develop CyA-dependent nephritis.


End-stage renal disease Immunosuppressive treatment Nephrosis Proteinuria Hematuria 



This work was supported by a grant from the Alma and K.A. Snellman Foundation to the first author for leave of absence.


  1. 1.
    Koskimies O, Mir S, Rapola J, Vilska J (1981) Henoch-Schönlein nephritis: long-term prognosis of unselected patients. Arch Dis Child 56:482–484PubMedGoogle Scholar
  2. 2.
    Ronkainen J, Nuutinen M, Koskimies O (2002) The adult kidney 24 years after childhood Henoch-Schönlein purpura: a retrospective cohort study. Lancet 360:666–670CrossRefPubMedGoogle Scholar
  3. 3.
    Ronkainen J, Ala-Houhala M, Huttunen N-P, Jahnukainen T, Koskimies O, Örmälä T, Nuutinen M (2003) Outcome of Henoch-Schönlein nephritis with nephrotic-range proteinuria. Clin Nephrol 60:80–84Google Scholar
  4. 4.
    Goldstein AR, White RH, Akuse R, Chantler C (1992) Long-term follow-up of childhood Henoch-Schönlein nephritis. Lancet 339:280–282PubMedGoogle Scholar
  5. 5.
    Niaudet P, Habib R (1998) Methylprednisolone pulse therapy in the treatment of severe forms of Schonlein-Henoch nephritis. Pediatr Nephrol 12:238–243CrossRefPubMedGoogle Scholar
  6. 6.
    Öner A, Tinaztepe K, Erdogan Ö (1995) The effect of triple therapy on rapidly progressive type of Henoch-Schönlein nephritis. Pediatr Nephrol 9:6–10Google Scholar
  7. 7.
    Foster BJ, Bernard C, Drummond KN, Sharma AK (2002) Effective therapy for severe Henoch-Schonlein purpura nephritis with prednisone and azathioprine: a clinical and histopathologic study. J Pediatr 136:370–375Google Scholar
  8. 8.
    Iijima K, Ito-Kariya S, Nakamura H, Yoshikawa N (1998) Multiple combined therapy for severe Henoch-Schonlein nephritis in children. Pediatr Nephrol 12:244–248CrossRefPubMedGoogle Scholar
  9. 9.
    Tanaka H, Suzuki K, Nakahata T, Ito E, Waga S (2003) Early treatment with oral immunosuppressants in severe proteinuric purpura nephritis. Pediatr Nephrol 18:347–350Google Scholar
  10. 10.
    Inoue Y, Iijima K, Nakamura H, Yoshikawa N (1999) Two-year cyclosporin treatment in children with steroid-dependent nephrotic syndrome. Pediatr Nephrol 13:33–38PubMedGoogle Scholar
  11. 11.
    Niaudet P and the French Society of Pediatric Nephrology (1994) Treatment of childhood steroid-resistant idiopathic nephrosis with a combination of cyclosporine and prednisone. J Pediatr 125:981–986PubMedGoogle Scholar
  12. 12.
    Ponticelli C, Rizzoni G, Edefonti A, Altieri P, Rivolta E, Rinaldi S, Ghio L, Lusvarghi E, Gusmano R, Locatelli F (1993) A randomized trial of cyclosporine in steroid-resistant idiopathic nephrotic syndrome. Kidney Int 43:1377–1384PubMedGoogle Scholar
  13. 13.
    Tanaka R, Yoshikawa N, Kitano Y, Ito H, Nakamura H (1993) Long-term cyclosporin treatment in children with steroid-dependent nephrotic syndrome. Pediatr Nephrol 7:249–252PubMedGoogle Scholar
  14. 14.
    Schmaldienst S, Winkler S, Breiteneder S, Hörl WH (1997) Severe nephrotic syndrome in a patient with Schönlein-Henoch purpura: complete remission after cyclosporin A. Nephrol Dial Transplant 12:790–792Google Scholar
  15. 15.
    Catalano C, Fabbian F, Bordin V, Di Landro D (1998) Failure of cyclosporine A in controlling Schoenlein-Henoch purpura. Nephrol Dial Transplant 13:1605–1606Google Scholar
  16. 16.
    Counahan R, Winterborn MH, White RHR, Heaton JM, Meadow SR, Bluett NH, Swetschin HS, Cameron JS, Chantler C (1977) Prognosis of Henoch-Schönlein nephritis in children. BMJ 2:11–14PubMedGoogle Scholar
  17. 17.
    Sairam VK, Kalia A, Rajaraman S, Travis LB (2002) Secondary resistance to cyclosporin A in children with nephrotic syndrome. Pediatr Nephrol 17:842–846Google Scholar
  18. 18.
    Thervet E, Pillebout E, Guillevin L (2003) Outcome after childhood Henoch-Schonlein purpura. Lancet 361:81–82CrossRefGoogle Scholar
  19. 19.
    Maschio G, Alberti D, Janin G, Locatelli F, Mann J, Motolese M, Ponticelli C, Ritz E, Zucchelli P (1996) Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. N Engl J Med 334:939–945Google Scholar
  20. 20.
    Hausberg M, Barenbrock M, Hohage H, Muller S, Heidenreich S, Rahn K-H (1999) ACE inhibitor versus β-blocker for the treatment of hypertension in renal allograft recipients. Hypertension 33:862–868PubMedGoogle Scholar
  21. 21.
    Anarat A, Noyan A, Gonlusen G, Duman N, Tuncer D (1996) Influence of enalapril on experimental cyclosporin A nephrotoxicity. Pediatr Nephrol 10:616–620Google Scholar
  22. 22.
    Seikaly MG, Prashner H, Nolde-Hurlbert B, Browne R (2002) Long-term clinical and pathological effect of cyclosporin in children with nephrosis. Pediatr Nephrol 14:214–217Google Scholar
  23. 23.
    Iijima K, Hamahira K, Tanaka R, Kobayashi A, Nozu K, Nakamura H, Yoshikawa N (2002) Risk factors for cyclosporine-induced tubulointerstitial lesions in children with minimal change nephrotic syndrome. Kidney Int 61:1801–1805CrossRefPubMedGoogle Scholar
  24. 24.
    Kano K, Kyo K, Yamada Y, Ito S, Ando T, Arisaka O (2001) Comparison between pre- and posttreatment clinical and renal biopsies in children receiving low doses cyclosporine-A for 2 years for steroid-dependent nephrotic syndrome. Clin Nephrol 52:19–24Google Scholar
  25. 25.
    Habib R, Niaudet P (1994) Comparison between pre and post treatment renal biopsies in children receiving cyclosporine for idiopathic nephrosis. Clin Nephrol 42:1446–1456Google Scholar

Copyright information

© IPNA 2003

Authors and Affiliations

  • Jaana Ronkainen
    • 1
  • Helena Autio-Harmainen
    • 2
  • Matti Nuutinen
    • 1
    Email author
  1. 1.Department of Pediatrics and AdolescenceOulu University HospitalFinland
  2. 2.Department of PathologyOulu University HospitalFinland

Personalised recommendations